Shinobi Therapeutics

Silent. Precise. Potent.

San Diego, United States · Founded 2015 · $119.0M raised

Employees
11–50
Founded
2015
Business Model
B2B
Total Funding
$119.0M
Last Round
$9.0M Extension RoundAug 2024
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Shinobi Therapeutics is a Japan-US biotechnology company developing immune-evasive iPSC-derived cell therapies for cancer and autoimmune diseases. Its proprietary Katana platform engineers hypoimmune iPS cells that evade both innate and antibody-mediated immune rejection, enabling off-the-shelf allogeneic therapies without the need for immunosuppression. Rooted in research from Kyoto University and UCSF, Shinobi launched in 2023 with a $51M Series A.

Summary

Shinobi Therapeutics is a Biotech company based in San Diego, United States, founded in 2015. It has raised $119.0M in total across 3 rounds, most recently a $9.0M Extension Round in Aug 2024. Investors include Yosemite, Mitsubishi UFJ Financial and Japanese Agency for Medical Research and Development (AMED).

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundSeries A ExtensionAug 2024
$9.0M

Sign up to see all 3 events

Funding: Series A through Grant. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Shinobi Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/shinobi-therapeutics"><img src="https://indexed.vc/api/badge/company/shinobi-therapeutics" alt="Shinobi Therapeutics on Indexed.vc" width="260" height="76" /></a>